Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

72 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Clinical and prognostic significance of changes in haemoglobin concentration during 1 year of androgen-deprivation therapy for hormone-naïve bone-metastatic prostate cancer.
Ebbinge M, Berglund A, Varenhorst E, Hedlund PO, Sandblom G; Scandinavian Prostate Cancer Group (SPCG)-5 Study Group. Ebbinge M, et al. Among authors: hedlund po. BJU Int. 2018 Oct;122(4):583-591. doi: 10.1111/bju.14227. Epub 2018 May 30. BJU Int. 2018. PMID: 29611275 Clinical Trial.
Parenteral estrogen versus combined androgen deprivation in the treatment of metastatic prostatic cancer -- Scandinavian Prostatic Cancer Group (SPCG) Study No. 5.
Hedlund PO, Ala-Opas M, Brekkan E, Damber JE, Damber L, Hagerman I, Haukaas S, Henriksson P, Iversen P, Pousette A, Rasmussen F, Salo J, Vaage S, Varenhorst E; Scandinavian Prostatic Cancer Group. Hedlund PO, et al. Scand J Urol Nephrol. 2002;36(6):405-13. doi: 10.1080/003655902762467549. Scand J Urol Nephrol. 2002. PMID: 12623503 Clinical Trial.
Parenteral estrogen versus combined androgen deprivation in the treatment of metastatic prostatic cancer: part 2. Final evaluation of the Scandinavian Prostatic Cancer Group (SPCG) Study No. 5.
Hedlund PO, Damber JE, Hagerman I, Haukaas S, Henriksson P, Iversen P, Johansson R, Klarskov P, Lundbeck F, Rasmussen F, Varenhorst E, Viitanen J; SPCG-5 Study Group. Hedlund PO, et al. Scand J Urol Nephrol. 2008;42(3):220-9. doi: 10.1080/00365590801943274. Scand J Urol Nephrol. 2008. PMID: 18432528 Clinical Trial.
Significance of pretreatment cardiovascular morbidity as a risk factor during treatment with parenteral oestrogen or combined androgen deprivation of 915 patients with metastasized prostate cancer: evaluation of cardiovascular events in a randomized trial.
Hedlund PO, Johansson R, Damber JE, Hagerman I, Henriksson P, Iversen P, Klarskov P, Mogensen P, Rasmussen F, Varenhorst E; SPCG-5 STUDY GROUP. Hedlund PO, et al. Scand J Urol Nephrol. 2011 Nov;45(5):346-53. doi: 10.3109/00365599.2011.585820. Epub 2011 May 31. Scand J Urol Nephrol. 2011. PMID: 21627403 Clinical Trial.
72 results